Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $12.8M | $13.3M | $28.6M | $10.2M | $27.5M | $23.6M | $106M |
| Revenue growth | — | — | — | — | 3.5% | 115.6% | -64.5% | 170.3% | -14.0% | 350.9% |
| Operating income | -$37.5M | -$33.4M | -$55.9M | -$20.3M | -$5.61M | $7.73M | -$42.6M | -$49.6M | -$87.0M | -$62.9M |
| Operating margin | — | — | — | -158.4% | -42.2% | 27.0% | -418.9% | -180.6% | -368.5% | -59.1% |
| Net income | -$16.5M | -$43.4M | -$56.5M | -$24.5M | -$12.8M | -$8.55M | -$26.8M | -$46.0M | -$106M | $83.2M |
| Net margin | — | — | — | -191.0% | -96.0% | -29.9% | -263.5% | -167.7% | -446.9% | 78.2% |
| EPS (diluted) | -$1.13 | -$2.96 | -$3.15 | -$13.23 | -$3.21 | -$2.11 | — | — | -$2.28 | $1.35 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.8M | -$33.1M | -$54.2M | -$23.7M | -$1.94M | $10.4M | -$18.7M | -$33.5M | -$69.7M | -$1.60M |
| Capital expenditures | $643K | $181K | $21.0K | $26.0K | $33.0K | $102K | $93.0K | $296K | $0.00 | $835K |
| Free cash flow | -$30.4M | -$33.3M | -$54.2M | -$23.8M | -$1.97M | $10.3M | -$18.8M | -$33.8M | -$69.7M | -$2.43M |
| Share buybacks | — | — | — | — | $0.00 | $2.81M | $4.72M | $3.45M | $0.00 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.8M | $10.9M | $18.4M | $3.22M | $4.21M | $112M | $65.5M | $43.0M | $33.8M | $62.4M |
| Total assets | $84.9M | $52.5M | $26.7M | $10.5M | $11.2M | $133M | $115M | $172M | $178M | $285M |
| Total liabilities | $104M | $110M | $93.3M | $85.0M | $77.6M | $5.82M | $40.2M | $110M | $138M | $130M |
| Long-term debt | — | $92.7M | $81.4M | $77.3M | $67.7M | — | — | $5.07M | $59.5M | $61.9M |
| Shareholders' equity | -$18.7M | -$57.5M | -$66.6M | -$74.5M | -$66.4M | $102M | $75.1M | $61.9M | $39.7M | $155M |
| Retained earnings | -$121M | -$165M | -$221M | -$246M | -$258M | -$267M | -$354M | -$400M | -$505M | -$422M |
| Shares (wtd avg diluted) | 14.6M | 14.7M | 1.65M | 2.27M | 3.98M | 29.8M | 34.5M | 35.5M | 46.3M | 57.3M |
Every figure is extracted from ZEVRA THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.